Free Trial
TSE:REUN

Reunion Neuroscience (REUN) Stock Price, News & Analysis

Reunion Neuroscience logo

About Reunion Neuroscience Stock (TSE:REUN)

Key Stats

Today's Range
N/A
50-Day Range
C$1.42
C$1.42
52-Week Range
N/A
Volume
339 shs
Average Volume
12,447 shs
Market Capitalization
C$16.64 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications. The company was formerly known as Field Trip Health Ltd. Reunion Neuroscience Inc. was founded in 2008 and is headquartered in Toronto, Canada.

Receive REUN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reunion Neuroscience and its competitors with MarketBeat's FREE daily newsletter.

REUN Stock News Headlines

Why are so many Roman statues headless?
Trump said you could learn something from this man
Early Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide victory. Yet one former Trump advisor says the picture is less rosy than it seems. “I’ve found a deep crack forming in the foundations of the US economy,” he says. “And before too long, it could tear our country apart.” It’s critical you learn more today, BEFORE it impacts your money and your retirement.
See More Headlines

REUN Stock Analysis - Frequently Asked Questions

Shares of REUN stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Reunion Neuroscience investors own include Meta Platforms (META) and BioLineRx (BLRX).

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
Healthcare
CIK
N/A
Fax
N/A
Employees
190
Year Founded
N/A

Profitability

Net Income
C$-38,100,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
C$4.86 million
Book Value
C$1.82 per share

Miscellaneous

Free Float
N/A
Market Cap
C$16.64 million
Optionable
Not Optionable
Beta
4.20
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

This page (TSE:REUN) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners